2024-09-10
On September 6, GlaxoSmithKline (GSK) announced positive results from the Phase III MATINEE study of Nucala (Mepolizumab) in the treatment of chronic obstructive pulmonary disease (COPD). The study was a 52-104 week multicenter, randomized, double-blind, placebo-controlled clinical trial (n=806) evaluating Mepolizumab (100mg once every 4 weeks, Subcutaneous injection) compared the efficacy and safety of placebo as an additional treatment option in addition to maintenance therapy in patients with moderate to severe COPD with frequently worsening disease and elevated blood eosinophils. The primary endpoint was the annual rate of exacerbation of moderate to severe COPD
